UNIVERSITY OF WASHINGTON MED CTR
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $381.2M
- Transactions
- 20,187
- Companies
- 40
- Average per transaction
- $18,882
Who reported the payments
| Pfizer | $46,196,324 |
| Merck | $32,338,032 |
| Amgen | $23,129,517 |
| AstraZeneca | $21,921,450 |
| Genentech, Inc. | $19,850,944 |
| Janssen Research & Development, LLC | $16,156,536 |
| E.r. Squibb & Sons, L.L.C. | $13,595,230 |
| Seagen Inc. | $12,504,016 |
| Novo Nordisk AS | $10,109,776 |
| AbbVie | $9,939,780 |
| Novartis | $9,077,995 |
| Gilead | $8,607,297 |
| Novavax Inc | $7,530,106 |
| Incyte Corporation | $6,190,880 |
| Eli Lilly | $6,068,308 |
| Sanofi US Services Inc. | $5,892,128 |
| Abbott | $4,474,584 |
| CSL Behring | $4,346,276 |
| Sanofi | $3,984,802 |
| Bristol Myers Squibb | $3,739,870 |
| F. Hoffmann-la Roche AG | $3,682,791 |
| Daiichi Sankyo Inc. | $3,615,718 |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,565,611 |
| Regeneron | $3,522,135 |
| Astrazeneca UK Limited | $3,383,617 |
| Edwards Lifesciences | $3,346,264 |
| EMD Serono, Inc. | $3,220,074 |
| Exelixis Inc. | $3,210,615 |
| Boehringer Ingelheim | $2,952,209 |
| Modernatx, Inc. | $2,790,773 |
| Biogen | $2,752,805 |
| Beigene, Ltd. | $2,694,378 |
| Vertex | $2,586,198 |
| Gen-probe, Inc. | $2,485,503 |
| GE HealthCare | $2,191,310 |
| Illumina, Inc. | $2,099,093 |
| Bayer | $1,872,580 |
| Ventana Medical Systems, Inc. | $1,767,277 |
| Jazz Pharmaceuticals Inc. | $1,619,329 |
| Deciphera Pharmaceuticals Inc. | $1,576,293 |